Mucin Binding Lectin Imaging Agents for Colonic Polyp Imaging


Available for licensing and commercial development is an imaging agent specific for colonic polyps that overexpress glycoprotein alpha-L-fucose containing mucins. Colon cancer is the second leading cause of cancer related deaths in the United States. The legume protein Ulex europaeus agglutinin I (UEA-1) has shown high specificity to alpha-L-fucose glycoproteins. Colonic mucosal neoplasia and/or polyps with high surface expression of alpha-L-fucosyl terminal residues can be specifically targeted with UEA-1 contrast agents. In one example, a computer tomography (CT) agent made from Iodine-127 (127I) labeled UEA-1 (I-UEA-1) and encapsulated into polymeric liposome nanoparticles was used to image murine colonic polyps. Ideally, the inventors envision a contrast agent that can be administered orally (e.g., liquid or pill form) and that would eliminate a patient’s need to drink harsh enema/contrast solutions prior to CT imaging.

Potential Commercial Applications: Competitive Advantages:
  • Colon cancer
  • Cancer imaging
  • Contrast agents
  • CT colonography
 


Inventors:

Ronald Summers (CC)  ➽ more inventions...

Jianwu Xie (CC)  ➽ more inventions...

Celeste Roney (CC)  ➽ more inventions...


Intellectual Property:
US Application No. 61/064,086
US Application No. 12/371,472

Publications:
J Xie et al. Oral contrast enhanced MicroCT virtual colonoscopy of APC knockout mouse colon polyp model. Gastroenterology. 2007 Apr;132(4), Suppl. 1, Abstract No. M1063, pp A-353 – A-354. PubMed abs
C Roney et al. Glycoprotein expression by adenomatous polyps of the colon. Proc. SPIE, Vol 6916, 691601 (2008); Published online 12 March 2008, doi:10.1117/12.769224.
SD O’Connor et al. Oral contrast adherence to polyps on CT colonography. J Comput Assist Tomogr. 2006 Jan-Feb;30(1):51-57.

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-254-2007/0
Updated: Mar 1, 2008